Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient.

Wang SJ, Asthana S, van Zante A, Heaton CM, Phuchareon J, Stein L, Higuchi S, Kishimoto T, Chiu CY, Olshen AB, McCormick F, Tetsu O.

Oral Oncol. 2017 Jun;69:1-10. doi: 10.1016/j.oraloncology.2017.03.020. Epub 2017 Apr 3.

2.

ETS-targeted therapy: can it substitute for MEK inhibitors?

Tetsu O, McCormick F.

Clin Transl Med. 2017 Dec;6(1):16. doi: 10.1186/s40169-017-0147-4. Epub 2017 May 2. Review.

3.

ETS1 inactivation causes innate drug resistance to EGFR inhibitors.

Tetsu O, Phuchareon J, Eisele DW, McCormick F.

Mol Cell Oncol. 2015 Aug 27;3(2):e1078924. doi: 10.1080/23723556.2015.1078924. eCollection 2016 Mar.

4.

Drug Resistance to EGFR Inhibitors in Lung Cancer.

Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F.

Chemotherapy. 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25. Review.

5.

AKT inactivation causes persistent drug tolerance to EGFR inhibitors.

Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F.

Pharmacol Res. 2015 Dec;102:132-7. doi: 10.1016/j.phrs.2015.09.022. Epub 2015 Oct 22. Review.

PMID:
26453958
6.

Resistance to EGFR-targeted therapy by Ets-1 inactivation.

Tetsu O, Eisele DW, McCormick F.

Cell Cycle. 2015;14(20):3211-2. doi: 10.1080/15384101.2015.1086200. No abstract available.

7.

EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Phuchareon J, McCormick F, Eisele DW, Tetsu O.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3855-63. doi: 10.1073/pnas.1510733112. Epub 2015 Jul 6.

8.

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.

You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L.

Oncotarget. 2015 Feb 28;6(6):4357-68.

9.

Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance.

Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O.

Transl Oncol. 2014 Dec;7(6):780-7. doi: 10.1016/j.tranon.2014.10.003.

10.

c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands.

Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O.

Transl Oncol. 2014 Oct 24;7(5):537-45. doi: 10.1016/j.tranon.2014.07.006. eCollection 2014 Oct.

11.

TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.

Heaton CM, Durr ML, Tetsu O, van Zante A, Wang SJ.

Laryngoscope. 2014 Jul;124(7):E267-73. doi: 10.1002/lary.24595. Epub 2014 Feb 20.

PMID:
24431303
12.

Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.

Ikeda Y, Oda K, Hiraike-Wada O, Koso T, Miyasaka A, Kashiyama T, Tanikawa M, Sone K, Nagasaka K, Maeda D, Kawana K, Nakagawa S, Fukayama M, Tetsu O, Fujii T, Yano T, Kozuma S.

Oncol Rep. 2013 Aug;30(2):584-8. doi: 10.3892/or.2013.2515. Epub 2013 Jun 3.

PMID:
23733133
13.
14.

Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2.

Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O.

PLoS One. 2009 Jun 25;4(6):e6040. doi: 10.1371/journal.pone.0006040.

15.

Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.

Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O.

Hum Mol Genet. 2008 Feb 1;17(3):419-30. Epub 2007 Nov 2.

PMID:
17981815
16.

A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation.

Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O.

PLoS One. 2006 Dec 27;1:e128.

17.

Cancer targets in the Ras pathway.

Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F.

Cold Spring Harb Symp Quant Biol. 2005;70:461-7. Review.

PMID:
16869784
18.

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA.

Science. 2006 Mar 3;311(5765):1287-90. Epub 2006 Jan 26.

19.

Proliferation of cancer cells despite CDK2 inhibition.

Tetsu O, McCormick F.

Cancer Cell. 2003 Mar;3(3):233-45.

20.

Method for screening ecdysone-inducible stable cell lines.

Wakita K, McCormick F, Tetsu O.

Biotechniques. 2001 Aug;31(2):414-8.

21.

A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics.

Wakita K, Tetsu O, McCormick F.

Cancer Res. 2001 Feb 1;61(3):854-8.

22.

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Tetsu O, McCormick F.

Nature. 1999 Apr 1;398(6726):422-6.

PMID:
10201372
23.

Mammalian Polycomb group genes are categorized as a new type of early response gene induced by B-cell receptor cross-linking.

Hasegawa M, Tetsu O, Kanno R, Inoue H, Ishihara H, Kamiyasu M, Taniguchi M, Kanno M.

Mol Immunol. 1998 Jun;35(9):559-63.

PMID:
9809583
24.

mel-18 negatively regulates cell cycle progression upon B cell antigen receptor stimulation through a cascade leading to c-myc/cdc25.

Tetsu O, Ishihara H, Kanno R, Kamiyasu M, Inoue H, Tokuhisa T, Taniguchi M, Kanno M.

Immunity. 1998 Oct;9(4):439-48.

25.

Successful gene transfer into murine pancreatic islets using polyamine transfection reagents.

Kenmochi T, Asano T, Nakagori T, Kaneko K, Nakajima K, Tetsu O, Jingu K, Iwashita C, Kainuma O, Tokoro Y, Sugamoto Y, Sakamoto K, Hatakeyama E, Yamada K, Isono K.

Transplant Proc. 1998 Mar;30(2):470-2. No abstract available.

PMID:
9532132
26.

The role of mel-18, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors.

Akasaka T, Tsuji K, Kawahira H, Kanno M, Harigaya K, Hu L, Ebihara Y, Nakahata T, Tetsu O, Taniguchi M, Koseki H.

Immunity. 1997 Jul;7(1):135-46.

27.
28.

A case of spontaneous intramural hematoma of the esophagus.

Furukawa H, Hara T, Taniguchi T, Tetsu O.

Gastroenterol Jpn. 1993 Feb;28(1):81-7. Review.

PMID:
8440426

Supplemental Content

Support Center